Company intelligence / Profile preview
Roussel-Uclaf
Paris, France
- Ownership
- Private
- Development stage
- Other
01
Overview
Roussel-Uclaf was a major French pharmaceutical company best known for the development of mifepristone (RU-486). The company was historically a leader in steroid research and antibiotic development before being absorbed into the entities that eventually formed Sanofi.
- Therapeutic areas
- EndocrinologyImmunologyWomen's HealthInfectious Diseases
- Modalities
- Small moleculeHormone
- Industry
- Pharma
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Hoechst AG
Beyond the preview
Go deeper on Roussel-Uclaf.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Roussel-Uclaf.